Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 7, 2007, Pages 1401-1409

  Ratner, Yael ^a   Gibel, Anatoly ^a   Yorkov, Vladimir ^a   Ritsner, Michael S ^a,b  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Efficacy; Long term; Naturalistic trial; Schizophrenia; Tolerability; Ziprasidone

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BIPERIDEN; BROTIZOLAM; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; CLOTIAPINE; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; MOOD STABILIZER; OLANZAPINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRIHEXYPHENIDYL; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; AKATHISIA; ANALYSIS OF COVARIANCE; ANOREXIA; ARTICLE; BRADYKINESIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; FEMALE; HUMAN; HYPERSALIVATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH DISEASE; TREMOR; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLES;

EID: 34548137741     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.06.008     Document Type: Article

References (41)

1. Addington D.E., Pantelis C., Dineen M., Benattia I., and Romano S.J. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 65 (2004) 1624-1633
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
3. Arato M., O'Connor R., and Meltzer H.Y. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17 (2002) 207-215
4. Ascher-Svanum H., Zhu B., Faries D., Landbloom R., Swartz M., and Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 21 6 (2006) 8
5. Beasley Jr. C.M., Stauffer V.L., Liu-Seifert H., Taylor C.C., Dunayevich E., and Davis J.M. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 27 (2007) 252-258
6. Chouinard G., and Margolese H.C. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76 (2005) 247-265
7. Chouinard G., Ross-Chouinard A., and AnnAnnable L. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7 (1980) 233
8. Chow S.C., and Liu J.P. Design and analysis of clinical trials: concepts and methodologies (1998), Wiley, New York
9. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. (1988), Lawrence Earlbaum Associates, Hillsdale, NJ
10. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M., et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20 (1999) 491-505
11. First M., Spitzer R.L., Gibbon M., and Williams J.B.W. SCID (DSM-IV) structured clinical interview for axis I DSM-IV disorders-patients edition (SCID-I.P) (1995), Biometrics Research Department, New York State Psychiatric Institute, New York
12. Glazer W.M., Conley R.R., and Citrome L. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE Study. CNS Spectr 11 9 Suppl 10 (2006) 1-13
13. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18 (1998) 296-304
14. Gunasekara N.S., Spencer C.M., and Keating G.M. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 62 (2002) 1217-1251
15. In: Guy W. (Ed). ECDEU assessment manual for psychopharmacology: publication ADM 76-338 (1976), US Department of Health, Education, and Welfare, Washington, DC 534-537
16. Hintze J.L. NCSS 6.0. Statistical System for Windows. User's Guide (1998), Number Cruncher Statistical Systems, Kaysville, Utah
17. Hirsch S., Kissling W., Bauml J., Power A., and O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63 (2002) 516-523
18. Hogan T.P., Awad A.G., and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13 (1983) 177-183
19. Kane J.M., Khanna S., Rajadhyaksha S., and Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 21 (2006) 21-28
20. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
21. Keck Jr. P., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140 (1998) 173-184
22. Keck P.E., Reeves K.R., Harrigan E.P., and Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled multicenter trials. J Clin Psychopharmacol 21 (2001) 27-35
23. Rummel C., Kissling W., and Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr. Res. 80 (2005) 85-97
24. Leucht S., McGrath J., White P., and Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence?. Clin Psychiatry 63 (2002) 218-224
25. Leucht S., Engel R.R., Bauml J., and Davis J.M. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophr Bull 33 (2007) 183-191
26. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
27. Liu-Seifert H., Adams D.H., and Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 23 3 (2005) 21
28. Novick D., Bousono M., Suarez D., Olivares J.M., Montejo A.L., Haro J.M., et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
29. Perkins D.O. Clinical trials in schizophrenia with results for the real world. CNS Spectr 11 7 Suppl 7 (2006) 9-13
30. Ritsner M.S., and Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1442-1452
31. Ritsner M., Modai I., Endicott J., Rivkin O., Nechamkin Y., Barak P., et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 61 (2000) 880-889
32. Ritsner M., Perelroyzen G., Kurs R., Jabarin M., and Ratner Y. Quality of life outcomes in schizophrenia patients treated with atypical and typical antipsychotic agents: a naturalistic comparative study. Int Clin Psychopharmacol 24 (2004) 582-591
33. Ritsner M., Perelroyzen G., Ilan H., and Gibel A. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24 (2004) 245-254
34. Schmidt A.W., Lebel L.A., Howard Jr. H.R., and Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425 (2001) 197-201
35. Sebastian C.S., Glazer W., and Buckley P.F. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 11 (2004) 329-342
36. Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., and Siu C.O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161 (2004) 1837-1847
37. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 162 (2005) 1535-1538
38. Stip E. Novel antipsychotics: issues and controversies: typicality of atypical antipsychotics. J Psychiatry Neurosci 52 (2000) 137-153
39. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163 (2006) 611-622
40. Weiden P.J., Simpson G.M., Potkin S.G., and O'Sullivan R.L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64 (2003) 580-588
41. White L., Harvey P.D., Opler L., and Lindenmayer J.P. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30 (1997) 263-274